Overview: Another Plavix user is claiming that the defects of the blood-thinning medication caused severe side effects. Following two bouts of gastrointestinal hemorrhaging and one episode of cerebral hemorrhaging, an Oklahoma man has decided to file a lawsuit against the drug makers. Parker Waichman LLP, a national law firm who often represents these types of victims, has filed a lawsuit on his behalf.
Product: Plavix (clopidogrel)
Manufacturer: Sanofi-Aventis, Bristol-Myers Squibb Co.
Side Effects & Complications
- Cerebral hemorrhage
- Thrombotic Thrombocytopenic Purpura (TTP)
- Gastrointestinal bleeding
- Internal bleeding
- Bone marrow damage
- Heart attack
Man Suffers Three Hemorrhages in Less than a Year
The lawsuit, which was filed on June 29th in the Supreme Court of the State of New York, County of New York, alleges that using Plavix caused severe bleeding and blames Sanofi-Aventis and Bristol-Myers Squibb for failing to alert consumers about these potentially fatal effects. This is a claim that has been made by many other similar suits. In this case, the Plaintiff started taking Plavix in March 2010. By December of 2010, he had suffered from a cerebral hemorrhage and two gastrointestinal hemorrhages. Allegations include severe and permanent injuries, physical impairment and disfigurement, physical pain and suffering, mental pain and suffering, loss of enjoyment of life and past, present and future sums of money incurred from medical expenses associated with monitoring and treating his injuries.
Research Suggests that Aspirin May be Just as Effective
Litigation has alleged numerous false claims on the part of Plavix manufacturers. Among these are the assertions that Plavix is a safer, more effective treatment option than Aspirin. Plavix and Aspirin are both used to prevent blood clot, stroke and heart attack in patients who have experienced these conditions in the past. However, as the lawsuit points, Plavix is much more expensive than Aspirin, with sales amounting to $42.8 billion since its approval in 1997. This gain in profit, the suit alleges, is the primary reason why the Defendants have not bothered to alert consumers about the bleeding risks, even though they were aware of them.
Despite being cheaper, research suggests that Aspirin may be an equally effective treatment compared to Plavix. This lawsuit, along with the many others, says that the manufacturers have tried to downplay to advantages of Aspirin by falsely touting Plavix as a superior version of the drug, with claims that it has greater benefits on cardiovascular and gastrointestinal health. However, studies published in the New England Journal of Medicine (NEJM) have called these claims into question. In 2005, the NEJM drew skepticism over the notion that Plavix is more tolerable on the stomach when researchers found that Aspirin taken with a heartburn pill results in significantly lower rates of recurrent ulcer bleeding compared to taking Plavix. The following year, the journal published a study suggesting that Aspirin alone was just as effective at preventing atherosclerotic events compared to Aspirin plus Plavix.